Levis, M. J., Erba, H. P., Montesinos, P., Vrhovac, R., Patkowska, E., Kim, H., … Perl, A. (2022). Quantum-First Trial: FLT3-ITD-Specific MRD Clearance Is Associated with Improved Overall Survival. In Blood (Vol. 140, pp. 546–548). American Society of Hematology. https://doi.org/10.1182/blood-2022-162739

Levis, Mark J., Harry P. Erba, Pau Montesinos, Radovan Vrhovac, Elzbieta Patkowska, Heeje Kim, Pavel Zak, et al. “Quantum-First Trial: FLT3-ITD-Specific MRD Clearance Is Associated with Improved Overall Survival.” In Blood, 140:546–48. American Society of Hematology, 2022. https://doi.org/10.1182/blood-2022-162739.

Levis MJ, Erba HP, Montesinos P, Vrhovac R, Patkowska E, Kim H, et al. Quantum-First Trial: FLT3-ITD-Specific MRD Clearance Is Associated with Improved Overall Survival. In: Blood. American Society of Hematology; 2022. p. 546–8.

Levis, Mark J., et al. “Quantum-First Trial: FLT3-ITD-Specific MRD Clearance Is Associated with Improved Overall Survival.” Blood, vol. 140, no. Supplement 1, American Society of Hematology, 2022, pp. 546–48. Crossref, doi:10.1182/blood-2022-162739.

Levis MJ, Erba HP, Montesinos P, Vrhovac R, Patkowska E, Kim H, Zak P, Wang P-N, Rohrbach JEC, Chang KCN, Hanyok J, Liu L, Kamel YM, Lesegretain A, Cortes JE, Sekeres MA, Dombret H, Amadori S, Wang J, Schlenk RF, Perl A. Quantum-First Trial: FLT3-ITD-Specific MRD Clearance Is Associated with Improved Overall Survival. Blood. American Society of Hematology; 2022. p. 546–548.